MedCity News October 14, 2021
Elise Reuter

The startup shared results of a prospective study showing its deep learning software detected melanoma with 93% sensitivity and 91% specificity. 

Not long after Paige cinched FDA clearance for its algorithm to flag potentially cancerous lesions, another digital pathology startup is touting the results of a study claiming its deep learning technology can detect melanoma with a high degree of accuracy.

Philadelphia-based Proscia shared the results of a prospective study testing its DermAI software on skin biopsies from two different laboratories. It found that its AI detected melanoma in situ and invasive melanoma with a sensitivity of 93% and a specificity of 91%.

Proscia has not yet published the results of the prospective study, but it hopes to  move toward...

Today's Sponsors

Qure4u
HLTH
ZeOmega

Today's Sponsors

Premier
TripleTree

Today's Sponsor

Transcarent

 
Topics: AI (Artificial Intelligence), Provider, Survey / Study, Technology, Trends
PCORI Invests $23.5M in Innovative mHealth, Telehealth Studies
Boehringer-backed digital health academy set for launch in UK
Medicare telehealth visits increased 63-fold during pandemic, study finds
Are You Using the Right Data to Power Your Digital Transformation?
Is it time for pathology to join the digital revolution?